ASCO 2026
Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma
Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patient...
Dai Chihara, MD, on a Regimen for Older, Unfit, or Frail Patients With Newly Diagnosed DLBCL
Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (r...
Walter Weber, MD, on Implant-Based Breast Reconstruction Techniques After Mastectomy
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) sig...
Laura Alder, MD, on New Data on Combination Therapy, Immunotherapy, and ADCs in Small Cell Lung Cancer
Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy b...
Lucy Gilbert, MD, on Overall Survival by Prior Taxane Use in the Phase III ROSELLA Trial
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overa...
Jamie E. Chaft, MD, FASCO, on Nivolumab After Surgery and Adjuvant Chemotherapy in NSCLC
Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses findings from ECOG-ACRIN EA5142/ALCHEMIST, a phase III randomized trial that evaluated the efficacy of adjuvant nivoluma...
Mohammed Al-Jumayli, MD, on a Digital Prehabilitation Model in Older Adults Undergoing Hepatobiliary Cancer Surgery
Mohammed Al-Jumayli, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the effects of the use of a multimodal, digitally supported prehabilitation program among adults aged 65 year...
William G. Wierda, MD, PhD, on Pirtobrutinib in Treatment-Naive Patients With CLL/SLL
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to b...
Lorenza Rimassa, MD, and David James Pinato, MD, PhD, on Expanding the HCC Treatment Landscape: TACE Combinations, Immunotherapies, and Bispecific Antibodies
Lorenza Rimassa, MD, of IRCCS Humanitas Research Hospital, and David James Pinato, MD, PhD, of Imperial College London, discuss positive phase III findings in intermediate-stage hepatocellular carcino...
John V. Heymach, MD, PhD, on First-Line Therapy for Advanced NSCLC With EGFR Exon 20 Insertions
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the primary analysis of the multinational phase III WU-KONG28 trial, which looked at sunvozertini...
Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer
Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median...
Mazyar Shadman, MD, on CLL/SLL: Sonorotoclax and Zanubrutinib
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanub...
Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic Breast Cancer: Maintenance Therapy Comparison
Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance th...
Elena Elimova, MD, on PD-L1 Subgroup Analysis From HERIZON-GEA-01
Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive lo...
Yashasvini Sampathkumar, MD, on Job Retention Intervention for Patients Undergoing Breast Cancer Therapy: Digital vs Print Format
Yashasvini Sampathkumar, MD, of Memorial Sloan Kettering Cancer Center, presents data on Talking to Employers and Medical Staff about Work (TEAMWork), an English/Spanish intervention. The English/Span...
GLP-1 RAs May Be Associated With Lower Breast Cancer Incidence
Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual M...
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response?
A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Resu...
Giannis S. Mountzios, MD, on SCLC: Intracranial Effect of Tarlatamab vs Chemotherapy
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs che...
Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III All...
Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC
Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the an...
Asaf Maoz, MD, on Pancreatic Cancer Screening: Potential Blood-Based Biomarkers
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveil...
Robert C. Stein, PhD, MBBChir, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Test-Directed Chemotherapy
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III random...
Marlana M. Orloff, MD, on Metastatic Uveal Melanoma: First-Line Therapy for HLA-A2–Negative Disease
Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choic...
Linda R. Mileshkin, MD, MBBS, FRACP, on Puxitatug Samrotecan for Endometrial or Ovarian Cancer
Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisome...
Kevin Kalinsky, MD, MS, FASCO, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-04
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among pat...
Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzum...
Brendan Heiden, MD, on Lung Cancer Screening Eligibility: Smoking Duration vs Pack-Years
Brendan Heiden, MD, of Washington University School of Medicine, discusses data from a unique real-world cohort of nearly 1 million patients in the Veterans Health Administration; researchers evaluate...
Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus pa...
Misty Dawn Shields, MD, PhD, on SCLC: Expert Point of View
Misty Dawn Shields, MD, PhD, of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, shares her perspective on two small cell lung cancer (SCLC) abstracts presented at this year’s mee...
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented ...
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared wit...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, ...
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with ...
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer
Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recur...
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers a...
Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
Results from the global phase III ASCENT-04 clinical trial found that sacituzumab govitecan combined with pembrolizumab improved progression-free survival 2 (PFS2) in patients with PD-L1–positive meta...
Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
According to findings from a phase III trial presented at the 2026 ASCO Annual Meeting (Abstract LBA6007), a low-cost regimen combining triple oral metronomic chemotherapy with ultra-low-dose immunoth...
HCC: TACE Plus STRIDE With or Without Lenvatinib
Results from the phase III EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab, regular inter...
Symptom-Monitoring App Helps Patients With Advanced Cancer Maintain Quality of Life
Use of a mobile app for proactive symptom monitoring helped patients with advanced cancer who were no longer receiving active anticancer treatment maintain their quality of life and reduced hospital u...
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) for first-line tr...
Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD...
Angimar Uriepero-Palma, MD, on CLL: Impact of SGLT2 Inhibitors on Patients With Diabetes
Angimar Uriepero-Palma, MD, of Jefferson Einstein Philadelphia Hospital, discusses a study that showed use of sodium-glucose cotransporter 2 (SGLT2) inhibitors was associated with longer 3-year overal...
Bjorn Henning Gronberg, MD, PhD, on Extensive-Stage SCLC: Concurrent TRT and Chemoimmunotherapy
Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibito...
Colton Jones, MD, on GLP-1 RAs for the Prevention of HCC in High-Risk Individuals
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 recep...
Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-ba...
Jason R. Westin, MD, FASC, on Updated Safety and Efficacy From the SUNMO Trial in LBCL
Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and po...
Xin Gao, MD, on Advanced or Metastatic Urothelial Carcinoma: LY4101174
Xin Gao, MD, of Massachusetts General Hospital and Harvard Medical School, discusses initial results from the phase I EXCEED trial of LY4101174, a Nectin-4–targeting antibody-drug conjugate, for patie...
Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer
Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigat...
Krishnan R. Patel, MD, on High-Risk Prostate Cancer: Clinico-Transcriptomic Risk Stratification
Krishnan R. Patel, MD, of the National Cancer Institute, discusses a combined analysis of the NRG/RTOG 9202, 9413, 9902, and 0521 trials that looked at using clinico-transcriptomic risk stratification...
Mark A. Dickson, MD, on Advanced Dedifferentiated Liposarcoma: SARC041 Trial
Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated li...
